Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14441MR)

This product GTTS-WQ14441MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14441MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14740MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ9651MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ9564MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ15990MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ12668MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ15726MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ11160MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ15087MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ST2146
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW